QNCX: LAM-001 shows promise as an inhaled mTOR inhibitor for multiple pulmonary diseases, with pivotal data ahead
LAM-001, an inhaled mTOR inhibitor, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with strong KOL support and promising early data. Key readouts are expected in Q1 2027 for BOS and Q1 2028 for PH-ILD, targeting significant unmet needs in pulmonary diseases.Based on Quince Therapeu…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.